ghk-cu injection human trial Peptide GHK-Cu Dosing: 1.7mg/Day Injectable (2026)

Mechanical changes such as disrupted fluid shear stress and stiffer arteries can result from plaque build-up and vessel narrowing present in many PAD cases (8890)

Brett Brechner, DO | Medical Director, Better Med Spa & Wellness Dr

In laboratory settings, Epithalon is primarily investigated as a potential modulator of telomerase activitythe enzyme complex involved in maintaining telomere integrity at the ends of chromosomes

The dosing ramps up across the first cycle: Days 1 through 15: 4 units (1 mg/day) Days 16 through 30: 8 units (2 mg/day) After 30 days, patients take 30 days off before starting the next cycle